200,000+ products from a single source!
sales@angenechem.com
Home > Imidazoles > 50-12-4
50-12-4 | 2,4-Imidazolidinedione, 5-ethyl-3-methyl-5-phenyl-
CAS No: 50-12-4 Catalog No: AG00DE3J MDL No:MFCD00022407
Product Description
Catalog Number:
AG00DE3J
Chemical Name:
2,4-Imidazolidinedione, 5-ethyl-3-methyl-5-phenyl-
CAS Number:
50-12-4
MDL Number:
MFCD00022407
IUPAC Name:
5-ethyl-3-methyl-5-phenylimidazolidine-2,4-dione
InChI:
InChI=1S/C12H14N2O2/c1-3-12(9-7-5-4-6-8-9)10(15)14(2)11(16)13-12/h4-8H,3H2,1-2H3,(H,13,16)
InChI Key:
GMHKMTDVRCWUDX-UHFFFAOYSA-N
EC Number:
200-012-8
NSC Number:
34652
Properties
Complexity:
310
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
218.106g/mol
Formal Charge:
0
Heavy Atom Count:
16
Hydrogen Bond Acceptor Count:
2
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
218.256g/mol
Monoisotopic Mass:
218.106g/mol
Rotatable Bond Count:
2
Topological Polar Surface Area:
49.4A^2
Undefined Atom Stereocenter Count:
1
Undefined Bond Stereocenter Count:
0
XLogP3:
1.5
Literature
| Title | Journal |
|---|---|
| Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury. | Archives of toxicology 20180101 |
| In vitro toxicological evaluation of NCS-382, a high-affinity antagonist of γ-hydroxybutyrate (GHB) binding. | Toxicology in vitro : an international journal published in association with BIBRA 20170401 |
| Mechanism-based inactivation of cytochrome P450 2B6 by isoimperatorin. | Chemico-biological interactions 20150125 |
| Histone deacetylase inhibitor valproic acid promotes the differentiation of human induced pluripotent stem cells into hepatocyte-like cells. | PloS one 20140101 |
| Interactions of sesquiterpenes zederone and germacrone with the human cytochrome P450 system. | Toxicology in vitro : an international journal published in association with BIBRA 20130901 |
| Bioactivation of sitaxentan in liver microsomes, hepatocytes, and expressed human P450s with characterization of the glutathione conjugate by liquid chromatography tandem mass spectrometry. | Chemical research in toxicology 20130617 |
| Direct and metabolism-dependent cytochrome P450 inhibition assays for evaluating drug-drug interactions. | Journal of applied toxicology : JAT 20130201 |
| Assessment of drug-drug interactions caused by metabolism-dependent cytochrome P450 inhibition. | Chemico-biological interactions 20120625 |
| Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. | Journal of medicinal chemistry 20120524 |
| Human cytochrome P450s: the work of Frederick Peter Guengerich. | The Journal of biological chemistry 20120504 |
| Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers. | European journal of clinical pharmacology 20120501 |
| Investigation of drug-drug interactions caused by human pregnane X receptor-mediated induction of CYP3A4 and CYP2C subfamilies in chimeric mice with a humanized liver. | Drug metabolism and disposition: the biological fate of chemicals 20120301 |
| Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19. | Journal of medicinal chemistry 20120209 |
| The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. | European journal of clinical pharmacology 20120101 |
| N-[3-(4-Fluoro-benz-yl)-2,4-dioxo-1,3-diaza-spiro-[4.5]dec-8-yl]-2-methyl-benzene-sulfonamide. | Acta crystallographica. Section E, Structure reports online 20120101 |
| N-{3-[2-(4-Fluoro-phen-oxy)eth-yl]-2,4-dioxo-1,3-diaza-spiro-[4.5]decan-7-yl}-4-meth-oxy-benzene-sulfonamide. | Acta crystallographica. Section E, Structure reports online 20120101 |
| Immunological response as a source to variability in drug metabolism and transport. | Frontiers in pharmacology 20120101 |
| Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. | Toxicological sciences : an official journal of the Society of Toxicology 20111201 |
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
| Characterization of inhibitory effects of perfluorooctane sulfonate on human hepatic cytochrome P450 isoenzymes: focusing on CYP2A6. | Chemico-biological interactions 20111115 |
| Dravet syndrome as epileptic encephalopathy: evidence from long-term course and neuropathology. | Brain : a journal of neurology 20111001 |
| Regional distribution of drug-metabolizing enzyme activities in the liver and small intestine of cynomolgus monkeys. | Drug metabolism and pharmacokinetics 20110601 |
| N-{3-[2-(4-Fluoro-phen-oxy)eth-yl]-2,4-dioxo-1,3-diaza-spiro-[4.5]decan-7-yl}-4-methyl-benzamide. | Acta crystallographica. Section E, Structure reports online 20110601 |
| Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation. | Drug metabolism and disposition: the biological fate of chemicals 20110501 |
| A UPLC-MS/MS assay of the 'Pittsburgh cocktail': six CYP probe-drug/metabolites from human plasma and urine using stable isotope dilution. | The Analyst 20110207 |
| Traditional Medicine to Modern Pharmacogenomics: Ayurveda Prakriti Type and CYP2C19 Gene Polymorphism Associated with the Metabolic Variability. | Evidence-based complementary and alternative medicine : eCAM 20110101 |
| CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. | BMC medical genetics 20110101 |
| Newly identified CYP2C93 is a functional enzyme in rhesus monkey, but not in cynomolgus monkey. | PloS one 20110101 |
| Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention. | Vascular health and risk management 20110101 |
| Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. | Addiction science & clinical practice 20101201 |
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. | Bioorganic & medicinal chemistry letters 20101101 |
| Can the genotype or phenotype of two polymorphic drug metabolising cytochrome P450-enzymes identify oral lichenoid drug eruptions? | Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 20100701 |
| Valproate-induced hyperammonemic encephalopathy, rapidly improved by i.v. carnitine and glucose/thiamine. | Scandinavian journal of gastroenterology 20100601 |
| Antiepileptic drug use, falls, fractures, and BMD in postmenopausal women: findings from the women's health initiative (WHI). | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20100401 |
| Identification and characterization of CYP2C18 in the cynomolgus macaque (Macaca fascicularis). | The Journal of veterinary medical science 20100201 |
| Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. | Drug metabolism and disposition: the biological fate of chemicals 20100101 |
| Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole. | Drug metabolism and disposition: the biological fate of chemicals 20091101 |
| Characterization of cytochrome P450-mediated bioactivation of a compound containing the chemical scaffold, 4,5-dihydropyrazole-1-carboxylic acid-(4-chlorophenyl amide), to a chemically reactive p-chlorophenyl isocyanate intermediate in human liver microsomes. | Chemical research in toxicology 20090901 |
| Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. | European journal of clinical pharmacology 20090401 |
| In vitro nimesulide studies toward understanding idiosyncratic hepatotoxicity: diiminoquinone formation and conjugation. | Chemical research in toxicology 20090101 |
| Interactions between herbal medicines and prescribed drugs: an updated systematic review. | Drugs 20090101 |
| Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. | BMC medical genetics 20090101 |
| Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects. | European journal of clinical pharmacology 20081201 |
| Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro. | Drug metabolism and disposition: the biological fate of chemicals 20081201 |
| Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. | Journal of medicinal chemistry 20081113 |
| CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype. | British journal of cancer 20081021 |
| Liquid chromatography/tandem mass spectrometry method for simultaneous evaluation of activities of five cytochrome P450s using a five-drug cocktail and application to cytochrome P450 phenotyping studies in rats. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080801 |
| Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening. | Drug metabolism and disposition: the biological fate of chemicals 20080701 |
| Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. | The AAPS journal 20080601 |
| Generation of mice transgenic for human CYP2C18 and CYP2C19: characterization of the sexually dimorphic gene and enzyme expression. | Drug metabolism and disposition: the biological fate of chemicals 20080501 |
| Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity. | European journal of clinical pharmacology 20080401 |
| A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens. | Journal of pharmacokinetics and pharmacodynamics 20080401 |
| CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles. | Drug metabolism and disposition: the biological fate of chemicals 20080301 |
| Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. | European journal of clinical pharmacology 20080201 |
| Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds. | Journal of pharmacological and toxicological methods 20080101 |
| Few alterations in clinical pathology and histopathology observed in a CYP2C18&19 humanized mice model. | Acta veterinaria Scandinavica 20080101 |
| High-throughput radiometric CYP2C19 inhibition assay using tritiated (S)-mephenytoin. | Drug metabolism and disposition: the biological fate of chemicals 20071001 |
| Identification of a novel laser dye substrate of mammalian cytochromes P450: application in rapid kinetic analysis, inhibitor screening, and directed evolution. | Journal of biomolecular screening 20070801 |
| Validated method for rapid inhibition screening of six cytochrome P450 enzymes by liquid chromatography-tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070601 |
| Evaluation of 3-O-methylfluorescein as a selective fluorometric substrate for CYP2C19 in human liver microsomes. | Drug metabolism and disposition: the biological fate of chemicals 20070601 |
| Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects. | Fundamental & clinical pharmacology 20070601 |
| Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis. | Journal of pharmaceutical and biomedical analysis 20070509 |
| Effect of sinomenine on human cytochrome P450 activity. | Clinica chimica acta; international journal of clinical chemistry 20070401 |
| Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population. | Xenobiotica; the fate of foreign compounds in biological systems 20070401 |
| Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the 'cocktail' approach. | Clinical pharmacology and therapeutics 20070201 |
| CYP2C76-mediated species difference in drug metabolism: a comparison of pitavastatin metabolism between monkeys and humans. | Xenobiotica; the fate of foreign compounds in biological systems 20070101 |
| The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. | Clinical pharmacokinetics 20070101 |
| Evolution and medicine: the long reach of 'Dr. Darwin'. | Philosophy, ethics, and humanities in medicine : PEHM 20070101 |
| In vitro metabolism of tributyltin and triphenyltin by human cytochrome P-450 isoforms. | Toxicology 20061207 |
| The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. | Life sciences 20061125 |
| Effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women. | Journal of clinical pharmacology 20061101 |
| Effects of individual ginsenosides, ginkgolides and flavonoids on CYP2C19 and CYP2D6 activity in human liver microsomes. | Clinical and experimental pharmacology & physiology 20060901 |
| Liver disease selectively modulates cytochrome P450--mediated metabolism. | Clinical pharmacology and therapeutics 20060901 |
| Validation of incorporating flurbiprofen into the Pittsburgh cocktail. | Clinical pharmacology and therapeutics 20060901 |
| CYP2C76, a novel cytochrome P450 in cynomolgus monkey, is a major CYP2C in liver, metabolizing tolbutamide and testosterone. | Molecular pharmacology 20060801 |
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| Cynomolgus monkey cytochrome P450 2C43: cDNA cloning, heterologous expression, purification and characterization. | Journal of biochemistry 20060501 |
| Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial. | European journal of clinical pharmacology 20060401 |
| Enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 4'-hydroxymephenytoin in human plasma and urine by liquid chromatography/tandem mass spectrometry. | Rapid communications in mass spectrometry : RCM 20060101 |
| A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. | Clinical pharmacology and therapeutics 20060101 |
| CYP2C19-mediated (S)-mephenytoin 4'-hydroxylation assayed by high-performance liquid chromatography with radiometric detection. | Methods in molecular biology (Clifton, N.J.) 20060101 |
| Evaluation of the activity of CYP2C19 in Gujrati and Marwadi subjects living in Mumbai (Bombay). | BMC clinical pharmacology 20060101 |
| Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. | Drug metabolism and disposition: the biological fate of chemicals 20051201 |
| Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. | Drug metabolism and disposition: the biological fate of chemicals 20051101 |
| Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. | Drug metabolism and disposition: the biological fate of chemicals 20050801 |
| Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. | European journal of clinical pharmacology 20050801 |
| Effect of age and postoperative time on cytochrome p450 enzyme activity following liver transplantation. | Journal of clinical pharmacology 20050601 |
| Cytochrome P-450 activity is differentially altered in severely injured patients. | Critical care medicine 20050301 |
| Lack of interaction of milnacipran with the cytochrome p450 isoenzymes frequently involved in the metabolism of antidepressants. | Clinical pharmacokinetics 20050101 |
| High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. | Rapid communications in mass spectrometry : RCM 20050101 |
| Bioequivalence revisited: influence of age and sex on CYP enzymes. | Clinical pharmacology and therapeutics 20041201 |
| Studies of binding modes of (S)-mephenytoin to wild types and mutants of cytochrome P450 2C19 and 2C9 using homology modeling and computational docking. | Pharmaceutical research 20041201 |
| Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors. | Archives of biochemistry and biophysics 20040901 |
| CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. | Drug metabolism and disposition: the biological fate of chemicals 20040901 |
| Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparison. | Xenobiotica; the fate of foreign compounds in biological systems 20040901 |
| Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. | Drug metabolism and disposition: the biological fate of chemicals 20040801 |
| The influence of St John's Wort on CYP2C19 activity with respect to genotype. | Journal of clinical pharmacology 20040601 |
| Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability. | Journal of clinical pharmacology 20040601 |
| Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. | Drug metabolism and disposition: the biological fate of chemicals 20040601 |
| Validated assays for human cytochrome P450 activities. | Drug metabolism and disposition: the biological fate of chemicals 20040601 |
| Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients. | Clinical pharmacology and therapeutics 20040601 |
| Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate. | Xenobiotica; the fate of foreign compounds in biological systems 20040501 |
| Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. | Xenobiotica; the fate of foreign compounds in biological systems 20040501 |
| Inhibition of cytochrome P450 activities by oleanolic acid and ursolic acid in human liver microsomes. | Life sciences 20040416 |
| Key structural features of ligands for activation of human pregnane X receptor. | Drug metabolism and disposition: the biological fate of chemicals 20040401 |
| Ethnic differences in genetic polymorphisms of CYP2D6, CYP2C19, CYP3As and MDR1/ABCB1. | Drug metabolism and pharmacokinetics 20040401 |
| Developmental expression of human hepatic CYP2C9 and CYP2C19. | The Journal of pharmacology and experimental therapeutics 20040301 |
| Sex-dependent modulation of treatment response. | Dialogues in clinical neuroscience 20040301 |
| Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. | Cellular and molecular neurobiology 20040201 |
| Quantification of mephenytoin and its metabolites 4'-hydroxymephenytoin and nirvanol in human urine using a simple sample processing method. | Rapid communications in mass spectrometry : RCM 20040101 |
| Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. | The Journal of pharmacology and experimental therapeutics 20031201 |
| Identification of the human cytochrome P450s responsible for the in vitro metabolism of a leukotriene B4 receptor antagonist, CP-195,543. | Xenobiotica; the fate of foreign compounds in biological systems 20031201 |
| Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. | British journal of clinical pharmacology 20031001 |
| Interferon-beta treatment in patients with multiple sclerosis does not alter CYP2C19 or CYP2D6 activity. | British journal of clinical pharmacology 20030901 |
| Capillary electrophoresis to assess drug metabolism induced in vitro using single CYP450 enzymes (Supersomes): application to the chiral metabolism of mephenytoin and methadone. | Electrophoresis 20030801 |
| Simultaneous enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 4'-hydroxymephenytoin in human plasma by liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030705 |
| Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. | Drug metabolism and disposition: the biological fate of chemicals 20030701 |
| Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. | Clinical pharmacology and therapeutics 20030701 |
| Do multiple cytochrome P450 isoforms contribute to parathion metabolism in man? | Archives of toxicology 20030601 |
| Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. | Drug metabolism and disposition: the biological fate of chemicals 20030501 |
| Interaction of serum proteins with CYP isoforms in human liver microsomes: inhibitory effects of human and bovine albumin, alpha-globulins, alpha-1-acid glycoproteins and gamma-globulins on CYP2C19 and CYP2D6. | Life sciences 20030314 |
| Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. | Clinical pharmacology and therapeutics 20030301 |
| Verification of the selectivity of (+)N-3-benzylnirvanol as a CYP2C19 inhibitor. | Drug metabolism and disposition: the biological fate of chemicals 20030301 |
| mRNA and protein expression of dog liver cytochromes P450 in relation to the metabolism of human CYP2C substrates. | Xenobiotica; the fate of foreign compounds in biological systems 20030301 |
| Neurochemical characteristics of the ventromedial hypothalamus in mediating the antiaversive effects of anxiolytics in different models of anxiety. | Neuroscience and behavioral physiology 20030301 |
| Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. | Progress in neuro-psychopharmacology & biological psychiatry 20030201 |
| Stereoselective determination of the CYP2C19 probe drug mephenytoin in human urine by gas chromatography-mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030105 |
| Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. | Archives of biochemistry and biophysics 20030101 |
| High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. | Journal of pharmaceutical and biomedical analysis 20030101 |
| Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. | Rapid communications in mass spectrometry : RCM 20030101 |
| In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. | Drug metabolism and pharmacokinetics 20030101 |
| Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. | Drug metabolism and disposition: the biological fate of chemicals 20021201 |
| Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19. | Epilepsy research 20021201 |
| Identification and functional characterization of new potentially defective alleles of human CYP2C19. | Pharmacogenetics 20021201 |
| Japanese pharmaceutical and regulatory environment. | Dialogues in clinical neuroscience 20021201 |
| Monolithic silica rod liquid chromatography with ultraviolet or fluorescence detection for metabolite analysis of cytochrome P450 marker reactions. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20021125 |
| Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. | Journal of cardiac failure 20021001 |
| An effective anticonvulsant prepared following a host-guest strategy that uses hydroxypropyl-beta-cyclodextrin and benzaldehyde semicarbazone. | Biochemical and biophysical research communications 20020816 |
| Amino acid residues affecting the activities of human cytochrome P450 2C9 and 2C19. | Drug metabolism and disposition: the biological fate of chemicals 20020801 |
| Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. | Pharmacogenetics 20020701 |
| Acute hypoxia and cytochrome P450-mediated hepatic drug metabolism in humans. | Clinical pharmacology and therapeutics 20020401 |
| CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population. | European journal of clinical pharmacology 20020401 |
| (+)-N-3-Benzyl-nirvanol and (-)-N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19. | Drug metabolism and disposition: the biological fate of chemicals 20020301 |
| Effect of growth hormone on hepatic cytochrome P450 activity in healthy elderly men. | Clinical pharmacology and therapeutics 20020301 |
| Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. | Biochemical pharmacology 20020301 |
| Effects of flavonoids isolated from Scutellariae radix on cytochrome P-450 activities in human liver microsomes. | Journal of toxicology and environmental health. Part A 20020301 |
| Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. | Pharmacology & toxicology 20020301 |
| Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects. | British journal of clinical pharmacology 20020201 |
| Pharmacokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity. | European journal of clinical pharmacology 20020201 |
| The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype. | European journal of clinical pharmacology 20020201 |
| Cytochrome p450 assays. | Current protocols in pharmacology 20020201 |
| The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. | European journal of clinical pharmacology 20011201 |
| Monoclonal antibodies specific and inhibitory to human cytochromes P450 2C8, 2C9, and 2C19. | Drug metabolism and disposition: the biological fate of chemicals 20011101 |
| Assessment of cytochrome P450 activity by a five-drug cocktail approach. | Clinical pharmacology and therapeutics 20011101 |
| An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). | British journal of clinical pharmacology 20011101 |
| Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. | British journal of clinical pharmacology 20011001 |
| Metabolism of vanoxerine, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, by human cytochrome P450 enzymes. | Drug metabolism and disposition: the biological fate of chemicals 20010901 |
| Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. | European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20010801 |
| Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test. | Therapeutic drug monitoring 20010601 |
| CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline. | European journal of clinical pharmacology 20010501 |
| Mephenytoin as a probe for CYP2C19 phenotyping:effect of sample storage, intra-individual reproducibility and occurrence of adverse events. | British journal of clinical pharmacology 20010501 |
| Moving toward genetic profiling in patient care: the scope and rationale of pharmacogenetic/ecogenetic investigation. | Drug metabolism and disposition: the biological fate of chemicals 20010401 |
| Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. | Journal of clinical psychopharmacology 20010401 |
| P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. | Therapeutic drug monitoring 20010401 |
| Metabolic characterization of the major human small intestinal cytochrome p450s. | Drug metabolism and disposition: the biological fate of chemicals 20010301 |
| Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin. | Clinical pharmacology and therapeutics 20010301 |
| Identification of human CYP2C19 residues that confer S-mephenytoin 4'-hydroxylation activity to CYP2C9. | Biochemistry 20010220 |
| Phenotype analysis of cytochrome P450 2C19 in Chinese subjects with mephenytoin S/R enantiomeric ratio in urine measured by chiral GC. | Biomedical chromatography : BMC 20010201 |
| Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. | British journal of clinical pharmacology 20010201 |
| In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. | British journal of clinical pharmacology 20000401 |
| Examination of purported probes of human CYP2B6. | Pharmacogenetics 19970601 |
| Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. | Pharmacogenetics 19970401 |
| Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. | Archives of toxicology 19970101 |
| Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate. | Journal of hepatology 19941201 |
| Drug metabolism and genetic polymorphism in subjects with previous halothane hepatitis. | Scandinavian journal of gastroenterology 19930801 |
| Synthesis and anticonvulsant activity of some new 2-substituted 3-aryl-4(3H)-quinazolinones. | Journal of medicinal chemistry 19900101 |
| Mechanism of iron potentiation of hepatic uroporphyria: studies in cultured chick embryo liver cells. | Hepatology (Baltimore, Md.) 19890901 |
| P-450 enzyme induction by 5-ethyl-5-phenylhydantoin and 5,5-diethylhydantoin, analogues of barbiturate tumor promoters phenobarbital and barbital, and promotion of liver and thyroid carcinogenesis initiated by N-nitrosodiethylamine in rats. | Cancer research 19880501 |
| Polymorphism of human cytochrome P-450. | Xenobiotica; the fate of foreign compounds in biological systems 19870301 |
| Mephenytoin: a reappraisal. | Epilepsia 19761201 |
| Generalized lymphadenopathy and nephrotic syndrome as a manifestation of mephenytoin (mesantoin) toxicity. | Pediatrics 19760101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.